Erik Engstrom - Smith Nephew Non-Executive Director
SNNUF Stock | USD 11.66 0.73 5.89% |
Director
Mr. Erik Engstrom is NonExecutive Independent Director of the Company since January 2015 and Member of the Audit Committee. He will join the Nomination Governance Committee in April 2019. Career and experience Erik is a graduate of the Stockholm School of Economics and of the Royal Institute of Technology in Stockholm . In 1988, he graduated with an MBA from Harvard Business School as a Fulbright Scholar. Erik commenced his career at McKinsey Company and then worked in publishing, latterly as President and COO of Random House Inc. and as President and CEO of Bantam Doubleday Dell, North America. In 2001, he moved on to be a partner at General Atlantic Partners, a private equity investment firm. Between 2004 and 2009, he was CEO of Elsevier, the division specialising in scientific and medical information and then from 2009 CEO of RELX Group. Skills and competencies Erik has successfully reshaped RELX Groups business in terms of portfolio and geographies. He brings a deep understanding of how technology can be used to transform a business and insight into the development of new commercial models that deliver attractive economics. His experience as a CEO of a global company gives him valuable insights as a member of our Audit and Nomination Governance Committees. since 2015.
Age | 54 |
Tenure | 9 years |
Professional Marks | MBA |
Phone | 44 1923 477 100 |
Web | https://www.smith-nephew.com |
Smith Nephew Management Efficiency
The company has return on total asset (ROA) of 0.0425 % which means that it generated a profit of $0.0425 on every $100 spent on assets. This is way below average. Similarly, it shows a return on equity (ROE) of 0.0925 %, meaning that it generated $0.0925 on every $100 dollars invested by stockholders. Smith Nephew's management efficiency ratios could be used to measure how well Smith Nephew manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
Showing other executives | DIRECTOR Age | ||
Alan Levine | Axogen Inc | 50 | |
Lawrence Waldman | Apyx Medical | 71 | |
Andreas Rihs | Sonova Holding AG | 72 | |
Filippo Passerini | Integer Holdings Corp | 63 | |
Charles Farkas | CONMED | 68 | |
John Andres | Apyx Medical | 59 | |
Michael Geraghty | Apyx Medical | 71 | |
Jerome Lande | CONMED | 45 | |
Fred Hite | Orthopediatrics Corp | 56 | |
Martin Maxwell | Integer Holdings Corp | 62 | |
Hugh Morrison | LivaNova PLC | 70 | |
Stephen Burns | Orthopediatrics Corp | 74 | |
Bernie Berry | Orthopediatrics Corp | 65 | |
James Lenehan | Medtronic PLC | 71 | |
Carlton Highsmith | Paragon 28 | 63 | |
Randall Hogan | Medtronic PLC | 64 | |
Dirk Kuyper | CONMED | 61 | |
Peter Robinson | Paragon 28 | 64 | |
Marc Stapley | Glaukos Corp | 50 | |
Mike Donovan | Axogen Inc | 53 | |
Jean Hobby | Integer Holdings Corp | 60 |
Management Performance
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 |
Smith Nephew plc Leadership Team
Elected by the shareholders, the Smith Nephew's board of directors comprises two types of representatives: Smith Nephew inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Smith. The board's role is to monitor Smith Nephew's management team and ensure that shareholders' interests are well served. Smith Nephew's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Smith Nephew's outside directors are responsible for providing unbiased perspectives on the board's policies.
Namal Nawana, CEO, Executive Director | ||
Michael Friedman, Non-Executive Independent Director | ||
Diogo MoreiraRato, President - Europe and Canada | ||
Alison Parkes, Chief Officer | ||
Skip Kiil, President - Orthopedics | ||
Erik Engstrom, Non-Executive Director | ||
Deepak Nath, CEO Director | ||
Matthew Stober, President - Global Operations | ||
Marc Owen, Non-Executive Director | ||
AnneFrancoise Nesmes, CFO Director | ||
Helen Barraclough, Company Counsel | ||
Rodrigo Bianchi, President IRAMEA | ||
Brian Larcombe, Senior Independent Non-Executive Director | ||
Elga Lohler, Chief Human Resource Officer | ||
Bradley Cannon, Sports Orthopaedics | ||
Gunthorp Oie, IR Contact Officer | ||
Roland Diggelmann, Non-Executive Director | ||
Helen Maye, Chief Human Resources Officer | ||
Vinita Bali, Non-Executive Director | ||
Simon Fraser, President - Advanced Wound Management | ||
Massimiliano Colella, President Europe - Middle East and Africa | ||
Olivier Bohuon, CEO, Director, Chairman of Disclosures Committee, Chairman of Executive Risk Committee and Member of Nomination and Governance Committee | ||
Graham Baker, CFO, Executive Director | ||
Cathy ORourke, Chief Legal and Compliance Officer | ||
Roberto Quarta, Non-Executive Independent Chairman of the Board | ||
Joe Metzger, VP Communications | ||
Cyrille Petit, Chief Corporate Development Officer | ||
Julie Brown, CFO, Director and Member of Disclosures Committee | ||
Glenn Warner, President - Advanced Wound Management | ||
Robin Freestone, Non-Executive Director | ||
Paul Connolly, Pres Operations | ||
Virginia Bottomley, Non-Executive Independent Director | ||
Phil Cowdy, Executive Vice President of Business Development & Corporate Affairs | ||
Angie Risley, Non-Executive Director | ||
Mark Gladwell, President - Global Operations | ||
Andrew Swift, VP Relations | ||
Vasant Padmanabhan, President - Research & Development | ||
Michael Frazzette, President - Advanced Surgical Devices | ||
Joseph Papa, Non-Executive Independent Director | ||
Ingeborg Oie, VP, Investor Relations | ||
Susan Swabey, Company Secretary | ||
Melissa Guerdan, Chief Quality and Regulatory Affairs Officer | ||
Philip Cowdy, Chief Officer | ||
Gordon Howe, President of Global Operations | ||
John Campo, Chief Legal Officer | ||
Brad Cannon, President Europe and Canada | ||
Ian Barlow, Non-Executive Independent Director | ||
Catheryn ORourke, Chief Legal Officer |
Smith Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Smith Nephew a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
Return On Equity | 0.0925 | |||
Return On Asset | 0.0425 | |||
Profit Margin | 0.1 % | |||
Operating Margin | 0.14 % | |||
Current Valuation | 14.08 B | |||
Shares Outstanding | 873.35 M | |||
Shares Owned By Insiders | 0.17 % | |||
Shares Owned By Institutions | 52.60 % | |||
Price To Earning | 23.41 X | |||
Price To Book | 2.12 X |
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Smith Nephew in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Smith Nephew's short interest history, or implied volatility extrapolated from Smith Nephew options trading.
Currently Active Assets on Macroaxis
Check out World Market Map to better understand how to build diversified portfolios, which includes a position in Smith Nephew plc. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in employment. You can also try the Portfolio Dashboard module to portfolio dashboard that provides centralized access to all your investments.
Complementary Tools for Smith Pink Sheet analysis
When running Smith Nephew's price analysis, check to measure Smith Nephew's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Smith Nephew is operating at the current time. Most of Smith Nephew's value examination focuses on studying past and present price action to predict the probability of Smith Nephew's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Smith Nephew's price. Additionally, you may evaluate how the addition of Smith Nephew to your portfolios can decrease your overall portfolio volatility.
Commodity Directory Find actively traded commodities issued by global exchanges | |
Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
FinTech Suite Use AI to screen and filter profitable investment opportunities | |
Price Transformation Use Price Transformation models to analyze the depth of different equity instruments across global markets | |
Alpha Finder Use alpha and beta coefficients to find investment opportunities after accounting for the risk |